Nucynta

Generic name: Tapentadol
Drug class: Opioids (narcotic analgesics)

Usage of Nucynta

Nucynta is an opioid pain medication. An opioid is sometimes called a narcotic.

Nucynta is a prescription medicine that is used to treat moderate to severe pain.

Nucynta ER (extended-release) is for around-the-clock treatment of pain that is not controlled by other medicines. Nucynta ER is not for use on an as-needed basis for pain.

Nucynta side effects

Get emergency medical help if you have signs of an allergic reaction to Nucynta: hives; chest pain, fast heartbeats, difficult breathing; swelling of your face, lips, tongue, or throat.

Opioid medicine can slow or stop your breathing, and death may occur. A person caring for you should give naloxone and/or seek emergency medical attention if you have slow breathing with long pauses, blue colored lips, or if you are hard to wake up.

Call your doctor at once if you have:

noisy breathing, sighing, shallow breathing, breathing that stops;

a light-headed feeling, like you might pass out;

agitation, feeling hot;

severe drowsiness or dizziness, confusion, problems with speech or balance;

a seizure;

serotonin syndrome - agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, diarrhea; or

low cortisol levels - nausea, vomiting, loss of appetite, dizziness, worsening tiredness or weakness.

Serious breathing problems may be more likely in older adults and in those who are debilitated or have wasting syndrome or chronic breathing disorders.

Common Nucynta side effects may include:

constipation, nausea, vomiting, stomach pain;

headache, feeling tired; or

drowsiness, dizziness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Nucynta

You should not use Nucynta if you are allergic to tapentadol, or if you have:

severe asthma or breathing problems;

a stomach or bowel obstruction (including paralytic ileus); or

if you have taken an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, or tranylcypromine.

To make sure Nucynta is safe for you, tell your doctor if you have ever had:

breathing problems, sleep apnea (breathing that stops during sleep);

a head injury, brain tumor, or seizures;

alcoholism or drug addiction, mental illness;

urination problems,

liver or kidney disease; or

problems with your gallbladder, pancreas, thyroid, or adrenal gland.

If you use opioid medicine while you are pregnant, your baby could become dependent tapentadol. This can cause life-threatening withdrawal symptoms in the baby after it is born. Babies born dependent on habit-forming medicine may need medical treatment for several weeks.

Ask a doctor before using Nucynta if you are breastfeeding. Tell your doctor if you notice severe drowsiness or slow breathing in the nursing baby.

Do not give Nucynta to a child.

Relate drugs

How to use Nucynta

Usual Adult Dose for Pain:

Individualize therapy taking into consideration severity of pain, response to therapy, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse:

Immediate-Release: Initial dose: 50 to 100 mg orally every 4 to 6 hours as needed for pain Day 1: A second dose may be administered as soon as 1 hour after the first dose if needed Subsequent dosing: 50, 75, or 100 mg orally every 4 to 6 hours; adjust dosing to maintain adequate analgesia with acceptable tolerability Maximum dose: 700 mg on day 1; 600 mg/day on subsequent days Comments: Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. Monitor closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and with each dose increase. Due to risks of addiction, abuse, and misuse, even at recommended doses, reserve use for patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products) have not been tolerated, or are not expected to be tolerated, or have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Usual Adult Dose for Chronic Pain:

Individualize therapy taking into consideration severity of pain, response to therapy, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse: Discontinue all other tapentadol and tramadol products prior to starting tapentadol extended-release tablets EXTENDED RELEASE TABLETS: Initial dose: 50 mg orally twice a day -Individually titrate to a dose that provides adequate analgesia and minimizes adverse reactions; dose increases should not exceed 50 mg twice a day every 3 days Maintenance dose: 100 mg to 250 mg orally twice a day Maximum dose: 500 mg/day CONVERSION from IMMEDIATE-RELEASE to EXTENDED-RELEASE: -Provide same total daily dose of tapentadol divided into 2 equal doses and administered orally twice a day approximately 12 hours apart CONVERSION from Other Opioids: -As there are no established conversion ratios from other opioids, initiate at 50 mg orally every 12 hours -Close observation and frequent titration are warranted until pain is controlled; monitor for signs and symptom of opioid withdrawal -Provide rescue medication with an appropriate dose of an immediate-release analgesic as appropriate Comments: -For patients with breakthrough pain a rescue medication with an appropriate dose of an immediate-release analgesic may be needed. -If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing dose. -Because of the risks of addiction, abuse, and misuse even at recommended doses, use should be limited to patients for whom alternative treatment options (e.g. non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient pain management. -This medicine is not for use as an as-needed analgesic.

Warnings

Do not use Nucynta if you have used a MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, tranylcypromine, and others.

You should not use Nucynta if you have severe breathing problems, or a bowel obstruction called paralytic ileus.

Nucynta can slow or stop your breathing, especially when you start using this medicine or whenever your dose is changed. Never take Nucynta in larger amounts, or for longer than prescribed. Do not crush, break, or open an extended-release tablet. Swallow it whole to avoid exposure to a potentially fatal dose.

Tapentadol may be habit-forming, even at regular doses. Take Nucynta exactly as prescribed by your doctor. Never share the medicine with another person. MISUSE OF NARCOTIC PAIN MEDICATION CAN CAUSE ADDICTION, OVERDOSE, OR DEATH, especially in a child or other person using the medicine without a prescription. Keep the medication in a place where others cannot get to it.

Tell your doctor if you are pregnant. Tapentadol may cause life-threatening withdrawal symptoms in a newborn if the mother has taken this medicine during pregnancy.

Fatal side effects can occur if you use Nucynta with alcohol, or with other drugs that cause drowsiness or slow your breathing.

What other drugs will affect Nucynta

Many other drugs can be dangerous when used with Nucynta. Tell your doctor if you also use:

medicine for allergies, asthma, blood pressure, motion sickness, irritable bowel, or overactive bladder;

other opioid medicines;

a benzodiazepine sedative like Valium, Klonopin, or Xanax;

sleep medicine, muscle relaxers, or other drugs that make you drowsy; or

drugs that affect serotonin, such as antidepressants, stimulants, or medicine for migraines or Parkinson's disease.

This list is not complete. Many drugs may interact with tapentadol, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.